YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
Swiss drugmaker Roche agreed to buy Philadelphia-based Spark Therapeutics for $4.8 billion.
Spark, which creates gene therapies for genetic diseases, is behind the blindness treatment called Luxturna, which costs $425,000 per eye.
"Spark Therapeutics' proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases," Roche CEO Severin Schwan said in a news release. "Spark Therapeutics' haemophilia A programme could become a new therapeutic option for people living with this disease."
Read more from Business Insider.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Banker pleads guilty to fraud scheme
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Caterpillar to acquire John Fabick Tractor Co.
Eric Schmitt introduces Modern Skies Act
Springfield airport to cut the ribbon on $35M in construction projects